Our single-center prospective study contributes a nuanced view of post-CABG rehabilitation outcomes in patients with/without T2DM and with/without CKD, pathologies for which an SGLT2 inhibitor has been proven beneficial during a cardiovascular rehabilitation program. Here, SLC5A2 is linked to type 2 diabetes mellitus.